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a b s t r a c t
The effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms of Parkinson’s
disease (PD) rarely have been investigated. Among these, sensory disturbances, including chronic pain
(CP), are frequent in these patients. The aim of this study was to evaluate the changes induced by deep
brain stimulation in the perception of sensory stimuli, either noxious or innocuous, mediated by small or
large nerve ﬁbers. Sensory detection and pain thresholds were assessed in 25 PD patients all in the off-
medication condition with the stimulator turned on or off (on- and off-stimulation conditions, respec-
tively). The relationship between the changes induced by surgery on quantitative sensory testing, spon-
taneous CP, and motor abilities were studied. Quantitative sensory test results obtained in PD patients
were compared with those of age-matched healthy subjects. Chronic pain was present in 72% of patients
before vs 36% after surgery (P = .019). Compared with healthy subjects, PD patients had an increased sen-
sitivity to innocuous thermal stimuli and mechanical pain, but a reduced sensitivity to innocuous
mechanical stimuli. In addition, they had an increased pain rating when painful thermal stimuli were
applied, particularly in the off-stimulation condition. In the on-stimulation condition, there was an
increased sensitivity to innocuous thermal stimuli but a reduced sensitivity to mechanical or thermal
pain. Pain provoked by thermal stimuli was reduced when the stimulator was turned on. Motor improve-
ment positively correlated with changes in warm detection and heat pain thresholds. Subthalamic
nucleus deep brain stimulation contributes to relieve pain associated with PD and speciﬁcally modulates
small ﬁber–mediated sensations.
 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
1. Introduction
Parkinson’s disease (PD) classically has been viewed as a disease
mainly affecting the motor system. However, nonmotor symptoms
(NMS) such as depression, pain, sexual problems, bowel inconti-
nence, and sleep disorders are present in a large majority of PD
patients, and their importance has been increasingly recognized
in recent years [3,15,33]. NMS are thought to be present from the
early stages of the disease and may be related to extension of Lewy
pathology to the nondopaminergic neuronal pathway [38]. Chronic
pain (CP) is one of the most frequent NMS, and it was found that
62% of a cohort of 450 PD patients had CP [20,27]. Mechanisms
involved in pain symptoms and their relation to nigrostriatal dopa-
minergic insufﬁciency and motor impairment are still poorly
understood [7,16].
Deep brain stimulation (DBS) has gained general use in the
management of refractory dyskinesias and motor ﬂuctuations in
PD patients [8,18]. The subthalamic nucleus (STN) is one of the
main targets of DBS, and its chronic stimulation can signiﬁcantly
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reduce motor symptoms. However, the impact of DBS on NMS has
been less often investigated. Two studies have shown that STN-
DBS could produce signiﬁcant pain relief in more than 80% of PD
patients, independently from motor effect [17,37]. Despite these
results, the mechanisms implicated in the possible analgesic effect
of STN-DBS remain speculative. The aim of our study was to eval-
uate the changes in painful and nonpainful sensory thresholds
brought about by STN-DBS in PD patients. We evaluated both large
and small ﬁber–mediated sensory thresholds using a comprehen-
sive battery of quantitative sensory testing (QST) in on-stimulation
vs off-stimulation conditions. In addition, we studied the relation-
ship between sensory changes and the improvement in motor
symptoms and CP under STN-DBS.
2. Methods
Thirty patients with idiopathic PD according to the UKPD Soci-
ety Brain Bank [6] treated by STN-DBS (Medtronic 3389 Minneap-
olis, MN) due to refractory motor ﬂuctuations were enrolled. The
study was approved by our institution ethic review board. All pa-
tients signed an informed consent form. All patients were treated
by STN-DBS for more than 1 year before study entry, and STN-
DBS stimulation parameters were considered to be optimized by
the time of the evaluation. Patients with cognitive decline (as as-
sessed by Mini-Mental State Examination (MMSE) score <25), ma-
jor depression according to Diagnostic and Statistical Manual of
Mental Disorders IV criteria, or a previous history or risk factor for
polyneuropathy (e.g., diabetes mellitus, alcohol abuse, vitamin
deﬁciency) were excluded. Patients who could not properly per-
form the tests in the off medication–off stimulation condition
due to PD severity were discarded from the analysis.
2.1. Clinical evaluation and CP assessment
Duration of the disease and STN-DBS treatment before evalua-
tion, motor scores of the Uniﬁed Parkinson’s Disease Rating Score
(UPDRS-III scores) in on- and off-medication conditions 3 months
before surgery, daily L-dopa equivalent dose at the time of the
study, and the presence of CP (before and after surgery under reg-
ular treatment) were recorded. The presence of pain and its char-
acteristics after surgery were assessed by the following tools:
1. Brazilian Portuguese version (B-PV) of the short McGill Pain
Questionnaire, including sensory and affective subscores [22].
2. B-PV of the Brief Pain Inventory (BPI), including BPI–pain sever-
ity index in the last 24 hours, current CP intensity (BPI–actual
pain), and interference (BPI–interference) [12].
3. B-PV of the Douleur Neuropathique-4 and Neuropathic Pain
Symptom Inventory [4,30].
4. B-PV of the Hospital Anxiety and Depression Scale (HAD),
including anxiety and depression subscores [36].
2.2. Experimental design
Dopaminergic medication was withdrawn overnight (at least
12 hours) before the evaluation, which included 2 sessions. First,
UPDRS-III and QST assessments were performed in on-stimulation,
off-medication (on-stim) condition. Second, after the DBS system
was switched off for 1 hour, UPDRS-III and QST assessments were
performed in off-stimulation, off-medication (off-stim) condition.
A neurologist experienced in PD and blinded to sensory symptoms
and QST results performed all UPDRS-III scorings. The presence of
CP before and after surgery was assessed on the day of the exper-
iment. Patients presenting CP at present were asked to ﬁll in pain
questionnaires and scales.
2.3. QST procedure
All participants went through a QST battery intended to assess
large ﬁber (Ab) and small ﬁber (Ad and C)–mediated somatic sen-
sory inputs, including experimental pain (EP) measurements using
suprathreshold stimuli. Tests were performed at both hands, over
the thenar eminence for thermal testing, and over the dorsum of
the hand for mechanical thresholds. Mechanical detection thresh-
olds (MDT) and mechanical pain thresholds (MPT) were measured
using calibrated von Frey hairs ranging from 0.008 to 300 g (NC
17775, Bioseb, France) [10]. We deﬁned MPT as the lowest pres-
sure that was considered painful by the patient. Vibratory and
thermal thresholds were measured using a VSA-3000/TSA-2001
device (Medoc, Ramat Yshai, Israel). Vibration detection threshold
(VDT) was measured at a constant frequency (100 Hz) and increas-
ing amplitude (0.1 to 130 lm). The method of limits was used, the
patients being instructed to press a button when they perceived
the beginning of vibratory sensation. For thermal detection thresh-
olds (warm detection threshold [WDT], cold detection threshold
[CDT]), the forced-choice method was used to avoid bias due to
increased motor reaction time related to PD. A contact thermode
(20  35 mm) was applied to the thenar eminence at a neutral
temperature of 32C. Temperature was increased or decreased at
a rate of 1C/s to 35C (WDT) or 29C (CDT). After each trial, pa-
tients had 5 seconds to answer yes or no according to the perceived
sensation: ‘‘yes’’ answers caused the system to decrease the tem-
perature difference to 1 C, and then to 0.3 C subsequently,
whereas ‘‘no’’ answers meant for further increases in temperature
differences. This protocol also included dummy stimulations, con-
sisting of trials during which there was no temperature change
from baseline. The ﬁnal threshold was considered after 3 consecu-
tive correct answers. Heat and cold pain thresholds (HPT, CPT)
were assessed by the methods of limits. Cooling and heating were
produced at a linear rate of 1C/s from a starting neutral tempera-
ture of 32C. Interstimulus intervals were 6 to 8 seconds for detec-
tion thresholds, 15 to 20 seconds for heat pain thresholds, and 20
to 30 seconds for cold pain thresholds. The thermode was gently
moved around the test area after each stimulation. Temperatures
did not exceed 50C for heat and 0 C for cold to avoid tissue dam-
age. The average of 3 trials was computed. All thermal thresholds
were expressed as absolute temperature values. Suprathreshold
heat stimulations (SuH) were also performed, with temperature
increasing at a linear rate of 2C/s from a starting neutral temper-
ature of 32C and kept constant for 2 seconds at 2 different target
temperatures (46C and 48C, in random order). EP intensity was
scored on a (0 to 100 mm) visual analogue scale (VAS). Infrathresh-
old cold stimulations (InC) were performed by decreasing temper-
ature from 32C to 10C and 5C. The 2 VAS scores obtained during
SuH (46C and 48C) on the one hand, and during InC (10C and
5C) on the other hand, were separately averaged to obtain a single
value of SuH and InC [26].
2.4. Healthy subjects and test-retest reproducibility
The QST results of PD patients were compared with those of 35
age-matched healthy subjects. Healthy subjects also underwent 2
consecutive QST batteries separated by 1 hour to assess test-retest
changes in QST measurements.
2.5. Statistical analyses
Descriptive statistics were used in the clinical characterization
of the sample. Because the Kolmogorov-Smirnov test revealed that
QST values did not have a normal distribution, we studied the
effect of STN-DBS (on-off vs off-off conditions) in PD patients and
test-retest in healthy subjects using the Wilcoxon signed rank test.
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Comparisons between QST values in PD patients and healthy sub-
jects were studied using the Mann-Whitney U test. Patients were
divided into 3 groups in the following way: group A, presence of
CP before but not after surgery; group B, presence of CP before
and after surgery; group C, absence of CP both before and after sur-
gery. UPDRS-III scores and QST results were compared among
these 3 groups. Correlation studies were performed (Spearman
test) between motor status (UPDRS-III) and QST values. The level
of statistical signiﬁcance was set at P < .05 and lowered accordingly
to take into account the Bonferroni correction for multiple
comparisons.
3. Results
3.1. PD patients: clinical characteristics and CP assessment
Five patients were excluded from the study because they were
not able to properly perform the entire QST battery in the off-stim
condition due to the severity of symptoms in the off-medication
condition. Then, 25 patients (6 women and 19 men, ages 42 to
70 years, mean ± SD 58.8 ± 8.3 years) completed the study
protocol.
All patients had advanced PD with a Hoehn and Yahr off-medi-
cation score P3. They had idiopathic PD for 15.1 ± 4.1 years and
were treated by bilateral STN-DBS for 2.4 ± 1.3 years before the
study. All patients had asymmetric motor symptoms at initial pre-
sentation, predominant on the right in 12 patients and on the left
in 13 patients. Preoperative UPDRS-III scores were 16.0 ± 9.0 and
41.5 ± 11.2 in on- and off-medication conditions, respectively. At
the time of the study, the mean L-dopa equivalent dose was
613 ± 60 mg/day and UPDRS-III scores were 25.8 ± 14.12 and
42.7 ± 11.6 in on-stim and off-stim conditions, respectively. Stimu-
lation parameters were as follows: the second contact from caudal
extremity of the lead was used as a single cathode in a unipolar
montage in 84% of the procedures: amplitudes (V) were (left/right
side): 2.7 ± 0.6/2.9 ± 0.6; pulse width (ls) was 90 ± 10.4/90 ± 13.7;
and frequency (Hz) was 130 ± 16.7/130 ± 16.7.
Eighteen patients (72%) presented CP before surgery and only 9
(36%) (v2 = 5.46; P = .019) continued to experience CP after STN-
DBS implantation under their usual pharmacological treatment.
All 9 patients with post-surgery pain underwent a full evaluation
of their current CP symptoms. Painful symptoms were asymmetri-
cal in all patients who remained in pain after surgery. In patients
who had motor symptoms initially predominant on the right side
(n = 5), pain predominated on the right in 3 patients and on the left
in the other 2. In those who had motor symptoms initially predom-
inant on the left side (n = 4), pain predominated on the right in 2
patients and on the left in the other 2. Sensory and affective sub-
scores of the short McGill Pain Questionnaire were 5.8 ± 3.9 and
2.3 ± 2.1, respectively. The BPI–pain severity index was 4.1 ± 1.7/
10, the BPI–actual pain was 4.5 ± 2.9/10, and the BPI–interference
was 4.1 ± 1.7/7. Only 1 patient had a Douleur Neuropathique-4
score P4, supporting CP of neuropathic origin. The Neuropathic
Pain Symptom Inventory score was 16.7 ± 18.0/100. Depression
Table 1
Inﬂuence of the presence of pain before and after deep brain stimulation of the subthalamic nucleus on motor performance assessed by the motor score of the UPDRS-III and QST
values in on-stimulation off-medication condition (on-stim) and the differential QST values between on-stim and off-stim conditions.
Group A Group B Group C KW test MW test
Pain before
only
Pain before/
after
No pain A  B A  C B  C
Motor performance
UPDRS-III score on-medication before surgery 11.6 ± 5.3 16.18.7 19.8 ± 12.7 NS – – –
UPDRS-III score off-medication before surgery 39.0 ± 10.9 44.5 ± 12.0 40.4 ± 10.5 NS – – –
UPDRS-III score on-stim after surgery 28.5 ± 18.8 26.0 ± 10.8 22.0 ± 10.3 NS – – –
UPDRS-III score off-stim after surgery 40.1 ± 14.0 44.0 ± 9.3 44.5 ± 11.2 NS – – –
Difference in UPDRS-III between off-medication and on-medication
before surgery
27.3 ± 9.0 28.3 ± 8.7 20.5 ± 5.1 P = .0320 NS P = .0236 P = .0243
Difference in UPDRS-III between off-medication before surgery and on-
stim after surgery
22.1 ± 9.4 21.0 ± 11.3 18.4 ± 5.5 NS – – –
Difference in UPDRS-III between off-stim and on-stim (after surgery) 11.5 ± 25.5 18.0 ± 15.1 16.9 ± 18.7 NS – – –
QST values in on-stim condition
VDT 2.7 ± 1.5 2.4 ± 1.6 3.2 ± 1.9 NS – – –
MDT 1.7 ± 1.1 2.1 ± 0.9 2.2 ± 0.7 NS – – –
MPT 10.7 ± 9.8 6.7 ± 3.7 5.4 ± 0.5 NS – – –
WDT 32.1 ± 1.8 32.8 ± 0.5 32.7 ± 0.4 NS – – –
CDT 31.9 ± 1.4 31.3 ± 0.7 31.4 ± 0.3 NS – – –
HPT 46.8 ± 3.2 44.4 ± 3.9 46.7 ± 2.7 NS – – –
CPT 14.9 ± 6.3 13.4 ± 6.7 9.9 ± 5.6 NS
SuH 38.2 ± 22.3 61.0 ± 19.5 39.2 ± 17.5 P = .0052 P = .0038 P = .0087 P = .0030
InC 39.7 ± 25.0 63.8 ± 24.0 37.0 ± 23.6 P = .0029 P = .0099 NS P = .0262
Differential QST values between on-stim and off-stim conditions
VDT 2.7 ± 1.5 2.4 ± 1.6 3.2 ± 1.9 NS – – –
MDT 0.1 ± 0.3 -0.5 ± 0.4 -0.1 ± 0.5 NS – – –
MPT 4.2 ± 11.2 0.9 ± 2.7 0.4 ± 0.4 NS – – –
WDT -0.3 ± 0.8 -0.1 ± 0.9 -0.5 ± 0.9 NS – – –
CDT 0.2 ± 1.0 0.1 ± 0.8 0.2 ± 0.7 NS – – –
HPT 1.1 ± 2.4 0.9 ± 4.7 2.0 ± 1.5 NS – – –
CPT -0.2 ± 6.1 -1.4 ± 3.9 -4.4 ± 5.4 NS – – –
SuH -3.5 ± 12.3 1.4 ± 21.3 -19. ± 19.0 P = .0224 NS NS P = .0262
InC -4.4 ± 14.1 -6.3 ± 11.1 -
19.0 ± 17.6
P = .0229 NS P = .0262 P = .0150
Values are presented as mean ± SD. Signiﬁcance of the KW and MW test set at P < .05 (underlined) and at P < .0166 for Bonferroni correction for multiple comparisons (bold
underlined).
UPDRS-III = Uniﬁed Parkinson’s Disease Rating Score; QST = quantitative sensory testing; KW = Kruskal-Wallis; MW =Mann-Whitney; VDT = vibration detection threshold;
MDT = mechanical detection threshold; MPT = mechanical pain threshold; WDT = warm detection threshold; CDT = cold detection threshold; HPT = heat pain threshold;
CPT = cold pain threshold; SuH = pain rating to suprathreshold heat stimulation; InC = pain rating to infrathreshold cold stimulation; NS = nonsigniﬁcant.
D. Ciampi de Andrade et al. / PAIN

153 (2012) 1107–1113 1109
and anxiety subscores of the HAD were 6.5 ± 3.6 and 7.2 ± 4.1,
respectively. CP was diffuse in 1 patient, located in the upper limbs
in 2 and in the lower limbs in 3, and was axial in 3 patients.
According to the usual classiﬁcation of PD-associated pain syn-
dromes [1], we found musculoskeletal CP in 6 patients (osteoar-
thritis n = 2; low back pain n = 4) and dystonic CP in 3 patients.
None had radicular or central neuropathic. Duration of disease
was not signiﬁcantly different in the 3 groups of patients. Interest-
ingly, patients without CP before or after surgery (group C) pre-
sented lower motor improvement in the preoperative L-dopa
charge test (on-medication–off-medication UPDRS-III score differ-
ence before surgery) than patients with CP (A and B) (Table 1).
3.2. QST results
3.2.1. On-stim vs off-stim
Because no threshold signiﬁcantly differed between the right
and left hands or between the most or least symptomatic side in
PD patients or in healthy subjects (all P > .20, Wilcoxon test),
results obtained from both hands were pooled before analysis.
All QST values are presented in Table 2. The detection of large
ﬁber–mediated sensations (MDT, VDT) did not change in PD
patients between on-stim and off-stim conditions. In contrast, PD
patients had a reduced sensitivity to mechanical pain (MPT
increase) and to thermal pain (HPT increase and CPT decrease) in
the on-stim condition, but they showed a higher sensitivity to
detect innocuous thermal sensations (WDT decrease and CDT
increase). Finally, VAS scores rating EP in SuH and InC were re-
duced when the stimulator was turned on. Only MPT increase
and the reduced EP ratings in InC were signiﬁcant after Bonferroni
correction. Interestingly, patients who still had CP after surgery
(group B) showed higher EP ratings for noxious thermal stimula-
tion than patients without CP after surgery (groups A and C). On
the other hand, patients without CP before or after surgery (group
C) presented the greatest modulation of thermal EP in the on-stim
vs off-stim condition (Table 1).
3.2.2. Test-retest reproducibility in healthy subjects
No thresholds signiﬁcantly differed between the ﬁrst and the
second examinations in healthy subjects, except the CDT, which
was higher at the ﬁrst measurement (ﬁrst vs second measurement
31.6 ± 0.2 and 31.5 ± 0.4, respectively; P = .0030). This result shows
that the QST results obtained in PD patients were not biased be-
cause of an unbalanced order of examination between on-stim
and off-stim conditions. Regarding the CDT increase at the second
test in PD patients, it cannot also be explained by a test-retest ef-
fect, because in contrast to PD patients, it decreased at the second
test in healthy subjects.
Table 2
Quantitative sensory testing in patients with PD in off-medication condition with subthalamic nucleus stimulation switched on (on-off) or off (off-off).
PD patients off-off PD patients on-off Healthy subjects off-off vs controls, P values* on-off vs controls, P values* off-off vs on-off, P values
VDT (lm) 2.7 ± 1.7 2.7 ± 1.6 1.4 ± 0.6 <.0001 <.0001 .9049
MDT (g) 2.0 ± 1.1 2.0 ± 0.9 0.9 ± 1.1 <.0001 <.0001 .9261
MPT (g) 5.8 ± 3.2 7.8 ± 6.6 13.3 ± 7.0 <.0001 .0002 <.0001
WDT (C) 32.8 ± 1.2 32.5 ± 1.1 35.3 ± 3.2 .001 <.0001 .0065
CDT (C) 31.3 ± 1.0 31.5 ± 1.0 27.9 ± 4.2 <.0001 <.0001 .0290
HPT (C) 44.6 ± 3.7 45.9 ± 3.5 45.7 ± 2.9 .0719 .4258 .0070
CPT (C) 14.8 ± 5.6 13.0 ± 6.4 11.5 ± 7.2 .0067 .4565 .0063
SuH (/100) 53.0 ± 24.4 46.7 ± 22.4 35.7 ± 26.4 .0014 .0328 .0233
InC (/100) 56.8 ± 29.8 47.6 ± 26.8 32.9 ± 25.4 .0002 .0058 .0001
Signiﬁcance set at P < .05 (underlined) and at P < .0055 for Bonferroni correction for multiple comparisons (bold underlined).
PD = Parkinson’s disease; VDT = vibration detection threshold; MDT = mechanical detection threshold; MPT = mechanical pain threshold; WDT = warm detection threshold;
CDT = cold detection threshold; HPT = heat pain threshold; CPT = cold pain threshold; SuH = pain rating to suprathreshold heat stimulation; InC = pain rating to infrathreshold
cold stimulation.
* Mann-Whitney U test.
 Wilcoxon Signed Rank Test.
Table 3
Literature data on the inﬂuence of subthalamic nucleus stimulation on quantitative sensory testing in patients with Parkinson’s disease under deep brain stimulation of the
subthalamic nucleus and comparisons with healthy subjects.
Sensitivity to:
Innocuous mechanical
stimuli
Mechanical
pain
Electrical
pain
Innocuous warm
stimuli
Heat pain Innocuous cold
stimuli
Cold pain
In on-stim condition
Gierthmühlen et al. Unchanged Unchanged Increased Unchanged Increased Increased
Spielberger et al. Unchanged Unchanged Unchanged Unchanged
Maruo et al. Increased Unchanged Increased Unchanged
This study Unchanged Decreased Increased Decreased Increased Decreased
Compared with healthy subjects
Djaldetti et al. Unchanged Unchanged Increased Unchanged Increased
Schestatsky et al. Unchanged Increased
Mylius et al. [25] Increased Increased
Zambito Marsala
et al.
Increased
Nolano et al. Decreased Decreased Decreased Decreased Decreased Unchanged
Vela et al. Unchanged
Mylius et al. [25] Increased Decreased
This study Decreased Increased Increased Unchanged or
increased
Increased Increased
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3.2.3. Comparisons between PD patients and healthy subjects
In both on-stim and off-stim conditions, PD patients had higher
MDT, VDT, and CDT and lower MPT and WDT compared with
healthy subjects. These differences were signiﬁcant after Bonfer-
roni correction. HPT did not differ in any condition. CPT was higher
in PD patients than in healthy subjects only in the off-stim condi-
tion, but this difference did not persist after Bonferroni correction.
Finally, VAS scores rating under EP in both SuH and InC were high-
er in PD patients than in healthy subjects, but the difference only
persisted in the off-stim condition after Bonferroni correction
(Table 2).
3.3. Correlation analyses
The changes induced by STN-DBS in UPDRS-III scores and QST
values correlated to WDT and HPT. The decrease in UPDRS-III score
correlated positively with HPT (increased sensitivity to heat pain;
rho = 0.504, P = .0012) and negatively to WDT (reduced sensitivity
to warm stimuli; rho = 0.370, P = .0152). All other correlations be-
tween motor changes in the on-stim condition and QST data, CP,
pain questionnaires, and scale scores were negative.
4. Discussion
The primary objective of this study was to investigate the im-
pact of STN-DBS on large and small ﬁber–dependent sensory
thresholds in off-medication PD patients. We found that DBS mod-
ulated exclusively small ﬁber–dependent sensory inputs by
increasing the sensitivity to innocuous thermal stimuli and by
reducing the sensitivity to mechanical and thermal painful stimuli.
Moreover, EP ratings decreased when painful thermal stimuli were
applied in on-stim vs off-stim condition. Thus, STN-DBS reduced CP
in parallel with the improvement of the discrimination of thermal
sensation.
Compared with healthy subjects, PD patients had an increased
sensitivity to mechanical pain and innocuous thermal stimuli,
but a reduced sensitivity to innocuous mechanical stimuli in both
on-stim and off-stim conditions. In addition, they had an increased
EP to painful thermal stimuli, particularly in the off-stim condition.
The fact that PD patients had a better detection of innocuous ther-
mal sensation than healthy subjects was an original result and may
be related to improvement in the methodological sensory detec-
tion techniques (forced choice) used in this study. These changes
could be translated by a net increase in the sensory limen (differ-
ence between detection and pain thresholds), indicating that under
STN-DBS only, there was a wider range of stimuli intensities per-
ceived as nonpainful when compared with the off-stim condition.
In the on-stim condition, sensory thresholds tended to normalize
according to the reference values measured in healthy subjects.
4.1. Literature data
The impact of STN-DBS on QST thresholds has been previously
investigated in 3 very recent reports (Table 3) [14,21,34]. Gier-
thmühlen et al. [14] found that STN-DBS increased the sensitivity
to innocuous thermal stimuli and also to cold pain. In contrast,
Spielberger et al. [34] did not observe any inﬂuence of STN-DBS
on thermal detection or pain thresholds. Finally, Maruo et al. [21]
found that STN-DBS increased the sensitivity to innocuous thermal
stimuli but not to painful thermal stimuli. In this latter study, com-
parisons with healthy subjects were also made: the sensitivity to
innocuous thermal stimuli was reduced in PD patients only in
the off-stim condition, whereas the sensitivity to thermal pain
did not differ between subjects and patients. Literature data
regarding QST results in PD compared with healthy subjects are
also summarized in Table 3 [9,10,24,28,31,36,39]. In general, these
studies were restricted to a few sensory modalities, mostly con-
cerning A-o and C conveyed sensory inputs. Detection thresholds
to cold stimuli and pain thresholds to either heat or cold stimuli
were seldom assessed, as well as EP rating to supra-threshold
stimulations.
4.2. Methodological limitations
In the present study, patients underwent a complete chronic
pain assessment exclusively in the postoperative period. Thus,
information on pain symptoms before surgery was obtained from
medical records and patient information, which could be subject
to assessment and recall bias.
Concerning the comparison of QST results between studies, it
should take into account the heterogeneity in the clinical presenta-
tion of PD patients among the studies or in the methods used to
perform the test, such as the size of the thermode probe or the
way to measure detection thresholds. For instance, a smaller ther-
mode surface was used in a previous study [21], which was likely
to yield different results from ours. More importantly, the method
of limits was the one used in virtually all previous studies. It means
that increased thresholds may be related, at least partially, to an
increased motor reaction time, especially in PD patients in the
off-stim condition. Because patients are asked to press a button
as soon as they perceive the change in temperature, a delay in mo-
tor reaction will cause an increase in the measured threshold unre-
lated to sensory detection. Our study was the ﬁrst to assess
thermal detection thresholds by using the method of forced choice
in PD patients. In this paradigm, different temperatures are pre-
sented to the participant, who has the time to answer and to decide
whether or not the stimuli were perceived, so that motor reaction
time has no inﬂuence on the ﬁnal result. Moreover, dummy stim-
ulations, during which no stimulus is presented, were randomly
applied. This trick is supposed to improve attention paid by pa-
tients for the successful completion of the task.
Cognitive dysfunction was not assessed in this study, based on
the third part of the UPDRS, which includes only motor evaluations
and not cognitive ones. The possible inﬂuence of cognitive disorder
on QST results was limited by the method we used to perform QST,
independent of reaction time as aforementioned. However, one
could argue that some PD patients, especially those with persistent
CP after surgery, would be more prone to present altered results
caused by pain-related attention deﬁcit [2] and effects of analgesic
drugs, for example. This is a potential limitation of our study, and
further studies evaluating the inﬂuence of cognitive factors on the
development of pain in PD patients, treated or not by DBS, will de-
serve attention.
4.3. General overview on QST changes induced by STN-DBS
STN-DBS is thought to modulate dopaminergic circuitry into the
brain [31]. Its motor effect positively correlates to preoperative L-
dopa response, which can predict a good outcome of DBS treat-
ment [11]. In the present study, we found that changes in WDT
and HPT correlated to motor improvement when the stimulator
was turned on. Experimental studies showed that dopaminergic
pathways are implicated in pain integration and modulation to
heat noxious stimulation [5,32,40]. Genetic factors also support
the association between low dopaminergic activity and high pain
sensitivity [35].
Other neurotransmitters are involved in PD pathophysiology,
such as substance P (SP) in the direct striato-pallidal pathway,
enkephalin (Enk) in the indirect striato-pallidal pathway, or GABA
in both pathways [19]. Because DBS acts on basal ganglia circuitry,
there is a possible role played by these nondopaminergic transmit-
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ters in the modulation of NMS, such as pain in PD. We showed that
patients with persisting CP after DBS (group B) had higher VAS
scores to painful stimuli (EP), whereas patients without pain before
or after surgery (group C) showed greater reduction of EP intensity
in the on-stim condition. One may hypothesize that patients of
group B may have a relatively less affected direct pathway, with
higher levels of SP (hyperalgesia), whereas patients of group C
could have a greater hyperactivity of the indirect pathway, associ-
ated with a more intense Enk action (analgesia). This would ac-
count for their different motor response to L-dopa and different
EP and CP proﬁles after DBS. Also, it would explain why patients
without CP before or after surgery (i.e., high Enk) showed the high-
est EP modulation under DBS [23]. This is further corroborated by
the fact that experimental studies showed that DBS reverses some
changes related to nigro-striatal denervation, such as GABA over-
expression, whereas it had no effects on other phenomena such
as overexpression of Enk in the indirect or under expression of
SP in the direct pathways [13,29]. This hypothesis needs to be
tested formally by experimental studies, but could provide new in-
sights on the relationship between pain, motor symptoms, and
their relief after treatment in PD patients.
4.4. Conclusion
This study showed that STN-DBS was associated with a
signiﬁcant relief of ongoing CP and changes in cutaneous sensory
thresholds, mostly thermal innocuous and noxious ones. In partic-
ular, the modulation of heat and warm detection was related to
DBS-induced motor improvement. These data will add to the
growing knowledge on the mechanisms of action of STN-DBS on
NMS in PD.
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